Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
70.81 USD | +1.32% | -0.27% | -0.85% |
Business Summary
Number of employees: 58
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 196 | 100.0 % | 131 | 100.0 % | -33.09% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 196 | 100.0 % | 131 | 100.0 % | -33.09% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 28/02/07 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 31/10/22 |
President | 49 | 05/08/15 | |
Andrew Reardon
LAW | General Counsel | 49 | 31/12/21 |
Corporate Officer/Principal | - | 02-19 | |
Karen Reeves
PRN | Corporate Officer/Principal | - | 02-19 |
Human Resources Officer | - | 30/11/94 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 28/02/03 |
John LaMattina
BRD | Director/Board Member | 74 | 31/01/11 |
Stephen Sabba
BRD | Director/Board Member | 64 | 03/08/08 |
Jason Aryeh
BRD | Director/Board Member | 56 | 26/09/06 |
Todd Davis
CEO | Chief Executive Officer | 63 | 28/02/07 |
Nancy Ryan Gray
BRD | Director/Board Member | 64 | 17/08/17 |
Director/Board Member | 55 | 25/09/23 | |
Jason Haas
BRD | Director/Board Member | 56 | 28/06/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,958,354 | 17,521,961 ( 97.57 %) | 0 | 97.57 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
3,616,077 | 3.31% | 296,518,314 $ |
Company contact information
Ligand Pharmaceuticals, Inc.
555 Heritage Drive Suite 200
33458, Jupiter
+858 550 7500
http://www.ligand.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.85% | 1.26B | |
+32.90% | 704B | |
+28.53% | 577B | |
-4.39% | 348B | |
+18.16% | 327B | |
+4.56% | 288B | |
+14.83% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.55% | 147B |
- Stock Market
- Equities
- LGND Stock
- Company Ligand Pharmaceuticals Incorporated